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THE aim of this study was to examine the basal release
of lysozyme from isolated human lung tissues. Meas-
urements of lysozyme in the fluids derived from lung
preparations  were  performed  using  a  rate-of-lysis
assay  subsequent  to  acidification  of  the  biological
samples. Lysozyme released from bronchial prepara-
tions into fluids was greater than that observed for
parenchymal tissues. The lysozyme quantities detec-
ted in bronchial fluids were not modified by removal
of  the  surface  epithelium.  Furthermore,  the  quan-
tities of lysozyme in bronchial fluids was correlated
with  the  size  of  the  bronchial  preparations.  These
results  suggest  that  the  lysozyme  was  principally
secreted by the human bronchi  (submucosal layer)
rather than by parenchyma tissues and that a greater
release was observed in the proximal airways.
Key  words:  Lysozyme,  Human  bronchus,  Parenchyma,
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Introduction
Lysozyme  has  been  described  to  be  present  in
glandular  serous  cells1,2 and  to  be  secreted  by
tracheal  explants  by  both  glandular  and  epithelial
cells.3 Furthermore,  neutrophils  and  macrophages
that  accumulate  within  the  airways  may  be  also  a
source of lysozyme.3,4
Since high concentrations of lysozyme have been
identified  in  airway  lavage  fluids5,6 and  in  expec-
torated sputum from patients with asthma,7 chronic
obstructive  lung  disease6–8 and  cystic  fibrosis,8 the
detection  of  this  enzyme  in  biological  fluids  from
patients with respiratory disease has frequently been
monitored  as  an  index  of  inflammation  in  human
airways. However, in these investigations the origin of
the lysozyme was not identified. Recently, Thompson
and coworkers6 determined the lysozyme concentra-
tions  in  both  bronchial  and  alveolar  lavage  fluid
samples, but the relative contribution of lysozyme by
proximal and distal airways was not discussed.
To  investigate  the  possibility  that  this  enzyme
might serve as a useful marker of airways secretion
and to examine the relative contribution of the upper
and lower respiratory tract to lysozyme release from
isolated  human  lung  tissues,  the  basal  release  of
lysozyme  was  measured  in  the  biological  fluids
derived from proximal and distal bronchial rings, as
well as from parenchymal tissues.
Material and methods
Functional studies
Human  lung  tissues  were  obtained  from  patients
(six  lung samples) who  had  undergone surgery  for
lung  carcinoma.  Tissues  were  obtained  from  the
resected  lung  at  a  distance  from  the  tumor  area.
Parenchymal  lung  tissues  were  cut  as  strips
(2/15 mm). The subsegmental bronchi (first to third
generation  bronchi)  were  dissected  free  from  par-
enchymal  tissue,  cut  as  rings  of  constant  length
(2mm,  internal  diameter)  and  weighed.  In  some
bronchial  rings,  the  surface  epithelium  was
removed  by  gently  rubbing  the  luminal  surface  of
the bronchial preparations with a moistened cotton
swab.  Bronchial  and  parenchymal  tissues  were
washed  with  a  physiological Tyrode’s  solution,  pH
7.4  and  allowed  to  equilibrate  in Tyrode’s  solution
for 1 h at 37°C in a humidified incubator (5% CO2/
air). Bronchial rings were placed in 1 ml of Tyrode’s
solution  while  parenchymal  tissues  were  equilibra-
ted in  10 ml of the Tyrode’s solution. At the end of
this  equilibration  period,  media  were  exchanged.
Bronchial and parenchymal tissues were replaced in
identical  volumes  of  fresh  Tyrode’s  solution  pre-
viously warmed for 1 h at 37°C. Media derived from
bronchial  and  parenchymal  tissues  were  collected
and  stored at  –20°C.
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Lysozymal activity was determined spectrophotomet-
rically by measuring the initial rate of lysis of a 3 mg/
ml  Micrococcus  lysodeikticus cell  wall  suspension
(Sigma Chemical Co., St Louis).9 Standard curves were
constructed  by  incubating  egg-white  lysozyme
(0.5–100 ng/ml;  Sigma  Chemical  Co.)  in  1.5 ml  of
50 mM potassium phosphate buffer, pH 7.4 contain-
ing M. lysodeikticus (300 m g/ml), sodium azide (0.1%;
Sigma Chemical Co.), BSA (1mg/ml; Sigma Chemical
Co.), mixed and incubated at 37°C for 2h. In parallel,
fluids (1ml) collected from bronchial and parenchy-
mal tissues were diluted in deionized water (1:4 v/v)
and acetic acid was added to adjust the pH to 4.5.
Samples  were  heated  at  100°C  for  2 min10 and
centrifuged  (3000 rpm  for  10 min)  to  precipitate
impurities. An aliquot of 200 m l of each treated sample
was added to 1.8 ml of potassium phosphate buffer
containing M. lysodeikticus (300 m g/ml), BSA (1mg/
ml), 0.1% sodium azide and incubated at 37°C for 2 h.
Change in turbidity was monitored at a wavelength of
450 nm with potassium phosphate buffer as blank. No
change of turbidity occurred under these conditions
in absence of enzyme. A standard curve was plotted as
optical  density  versus  the  concentration  of
lysozyme.
Calculation
Coefficients of variation of the lowest and the highest
value  of  the  standard  curve  were  calculated  by
dividing  the  standard  deviation  by  the  mean  and
expressed  as  a  percentage.  The  concentration  of
lysozyme detected in the fluids derived from human
bronchial  and  parenchymal  preparations  are
expressed  as  ng/ml  and  were  estimated  from  the
standard curves. All results are means±SEM. Statistical
analysis were performed using the Student’s t-test. A
value  (P<0.05)  was  taken  as  an  indication  of
significance.
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FIG. 1. Calibration curve of the rate-of-lysis assay based on the bactericidal activity of lysozyme. Data points represent the
means±SEM (n=15) for optical density measured in triplicate at 450nm at each egg-white standard concentration (0.5–100ng/
ml).Results
The  mean  standard  curve  (n=15)  for  the  lysozyme
concentration measurements obtained with the egg-
white lysozyme is presented in Fig. 1. The assay was
sensitive since the linear part of the curve allowed the
determination of lysozyme concentrations from 100
to 1.6 ng/ml. This assay was also highly reproductive
since the coefficient of variation for the highest and
the lowest value were 3% and 6%, respectively.
Whereas  no  significant  alteration  of  the  standard
curve  was  observed  when  the  egg-white  lysozyme
was  acidified  and  heated  (data  not  shown),  the
lysozyme concentrations determined in treated bron-
chial  fluids  were  significantly  increased  compared
with the contents of untreated fluids derived from the
same bronchial preparations (Table 1).
The  lysozyme  quantities  of  fluids  derived  from
bronchial rings were then compared with the concen-
trations detected in parenchymal fluids subsequent to
acidification  and  heating  of  the  samples.  Approx-
imatively two-fold higher concentrations were meas-
ured in bronchial fluids compared with the amounts
detected  in  fluids  derived  from  the  parenchymal
tissues  (data  not  shown).  Furthermore,  the  mean
parenchyma wet weight was 19-fold higher than the
bronchial wet weight, suggesting that the lysozyme
quantities determined in treated bronchial fluids were
largely dependent on the lung tissue wet weight from
which samples derived.
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Table 1. Effects of acidification and heating on the lysozyme
detection
Bronchial fluids Lysozyme (ng/ml)
Untreated 280±47
Acidified and heated 507±65*
Values are means±SEM (three preparations from three different lung
samples; mean bronchial tissue wet weight: 900±30mg).
*indicates  that  values  are  significantly  different  from  untreated
samples (P<0.05; Student’s t test).
FIG.  2.  Lysozyme  release  corrected  by  tissue  wet  weight
and  expressed  as  ng/ml/mg  of  tissue  wet  weight  from
human bronchial and parenchymal preparations. Values are
means±SEM from 40 bronchial rings and 10 parenchymal
preparations from  six  lung samples.  ***indicates P<0.005
(Student’s t-test).
FIG.  3.  Lysozyme  quantities  (ng/ml)  contained  in  fluids
derived from human bronchial preparations either with (j )
or without (h ) surface epithelium. Values are means±SEM
(10–40 bronchial rings from three to six lung samples; mean
tissue wet weight: 200±70mg).Since  significant  correlations  were  observed
between the tissue wet weight and the quantities of
lysozyme  detected  in  fluids  derived  from  either
human  bronchial  rings  (correlation  coefficient,
r=0.86;  P<0.05)  or  lung  parenchyma  (correlation
coefficient,  r=0.63;  P<0.05),  normalization  of  the
lysozyme  fluid  contents  to  tissue  wet  weight  was
performed. The lysozyme quantities detected in bron-
chial fluids were significantly higher (approximately,
15-fold) than the quantities of lysozyme detected in
the parenchymal fluids (Fig. 2).
No significant difference in the lysozyme quantities
was observed in the fluids collected from bronchial
rings  with  an intact epithelium compared  with the
quantities detected in fluids derived from rings where
the surface epithelium had been removed (Fig. 3).
Discussion
These  results  suggest  that  the  measurements  of
lysozyme in the biological fluids derived from human
bronchial  and  parenchymal  tissues  subsequent  to
acidification  and  heating  facilitated  the  lysozyme
detection. A predominent release of this enzyme from
human bronchial rings, particularly from submucosal
glands  was  observed,  whereas  lung  parenchymal
tissues released markedly less quantities of lysozyme.
The  results  also  suggested  that  proximal  airways
secreted  higher  lysozyme  quantities  than  distal
bronchi.
The  determination  of  the  lysozyme  contents  in
fluids  collected  from  human  bronchial  rings  and
parenchymal  tissues  was  performed  using  a  highly
sensitive and reproductive spectrophotometric assay
based on the bacteriolytic activity of this enzyme.9,11
This assay allowed the detection of lysozyme levels as
low as 1.6 ng/ml in biological fluids. However, strong
interactions between the lysozyme and mucus glyco-
proteins  have  been  reported  due  to  their  negative
charge, leading to the aggregation of these proteins
and  to  the  difficulty  in  evaluating  the  lysozyme
quantities  exactly  in  biological  samples.12 Several
years ago, Joll` es and Petit10 described a treatment of
salivary  fluids  by  acidifing  and  heating  samples,
which  purified  the  enzyme  without  altering  the
lysozymal activity.10,13 However, this observation has
been  largely  neglected  in  the  methods  used  to
evaluate  the  lysozyme  concentrations  in  biological
samples. The present report clearly showed that the
lysozyme quantities detected in the treated bronchial
fluids were significantly increased compared with the
contents of untreated samples. These data supported
the notion that the lysosomal activity was stable after
acidification  and  heating  of  samples  and  suggested
that  this  treatment  was  suitable  for  purifying  the
enzyme and thereby facilitated the determination of
the quantities detected by the rate-of-lysis assay.
The lysozyme quantities detected in human bron-
chial fluids were approximatively  1 m g/ml,  whereas
lower quantities of lysozyme (660 ng/ml) were detec-
ted  in  the  fluids  derived  from  parenchymal  tissues
(present report). Although high concentrations of this
enzyme have been detected in airway lavages or nasal
fluids  from  patients  without  respiratory  distress
(approximatively, 10 m g/ml),5,6 the differences in the
levels of lysozyme detected in bronchial fluids may be
explained  by  the  fact  that  measurements  (present
report)  were  performed  in  a  model  of  isolated
bronchial rings which were periodically rinsed with
fresh medium. Previous investigations reported that
the bronchial sample lavage fluid concentrations of
lysozyme were higher than alveolar sample contents
after normalization of the quantities to albumin.6 In
the present study, when the lysozyme quantities were
corrected by tissues wet weight from which biolog-
ical  fluids  were  derived,  bronchial  contents  were
markedly  higher  (approximately,  15-fold)  compared
with the parenchymal fluid concentrations, support-
ing the previous observations. In human lung tissues,
Klockars and coworkers4 reported that alveolar epi-
thelium  was  devoid  of  lysozyme  while  an  intense
lysozyme  immunohistochemical  labelling  was
observed in neutrophils and monocytes which accu-
mulate within the airways. In view of these investiga-
tions, the present data suggested that  the lysozyme
detected  in  parenchymal  fluids  may  be  due  to  the
degranulation of macrophages and neutrophils pres-
ent in the lung connective tissue.
The  present  results  showed  that  the  lysozyme
concentrations were highly correlated with the bron-
chial tissues wet weight, suggesting that the lysozyme
source  was  greater  in  human  proximal  bronchi
compared to the distal airways. Recent investigations
reported  that  goat  airway  bronchioles  and  alveolar
ducts  were  essentially  constituted  of  six cell types,
among  which  glandular  structures  were  not  pres-
ent.14 These  data  supported  the  notion  that  in  the
more distal portion of the lung, the glandular volume
was smaller.
The  present  study  also  demonstrated  that  the
removal  of  the  surface  epithelium  from  human
bronchial rings did not modify the lysozyme release
from  these  preparations. These  data  suggested  that
the  submucosal  layer  was  the  principal  source  of
lysozyme and supported previous immunohistochem-
ical  observations,  which  showed  that  the  lysozyme
was  secreted  from  the  bronchial  glandular  serous
cells.1,2
In  conclusion,  the  present  report  demonstrated
that a treatment (acidification and heating) of biolog-
ical fluids derived from lung samples facilitated the
detection  of  lysozyme  by  the  spectrophotometric
rate-of-lysis  assay.  In  addition,  the  measurements  of
lysozyme showed that this enzyme was released from
human  bronchial  rings,  specifically  from  glandular
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parenchyma.  Since  various  investigations  reported
that lysozyme levels were elevated in association with
respiratory  distress,  such  as  chronic  bronchitis  and
asthma6 –8 where glandular tissue volume was high,
these  data  suggested  that  the  lysozyme  may  be  a
marker of the secretory activity of glands and could
be used in the study of agents regulating the glandular
secretion.
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